Besides, tumor-enhanced expression of several transporter proteins for glucose and amino acids have been well documented, implicating nutrient signaling in tumor cell growth and survival.41–44 Therefore, future studies should aim to elucidate the functional significance of these transporters in GBM pathogenesis, and investigate the potential clinical implications of utilizing tumor microenvironment-driven OATP expression for drug targeting. This evidence concerns the gene SLCO1A2 and glioblastoma.